A detailed history of Orion Portfolio Solutions, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Orion Portfolio Solutions, LLC holds 59,257 shares of EXEL stock, worth $2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
59,257
Previous 59,264 0.01%
Holding current value
$2 Million
Previous $1.33 Million 15.48%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$21.96 - $27.6 $153 - $193
-7 Reduced 0.01%
59,257 $1.54 Million
Q2 2024

Aug 13, 2024

BUY
$20.34 - $23.73 $119,599 - $139,532
5,880 Added 11.01%
59,264 $1.33 Million
Q1 2024

May 09, 2024

SELL
$20.17 - $23.93 $57,726 - $68,487
-2,862 Reduced 5.09%
53,384 $1.27 Million
Q4 2023

Feb 09, 2024

SELL
$19.25 - $24.13 $69,473 - $87,085
-3,609 Reduced 6.03%
56,246 $1.35 Million
Q3 2023

Nov 01, 2023

SELL
$19.04 - $22.74 $67,401 - $80,499
-3,540 Reduced 5.58%
59,855 $1.31 Million
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $39,501 - $44,523
-2,174 Reduced 3.32%
63,395 $1.21 Million
Q1 2023

Aug 30, 2023

BUY
$16.3 - $19.41 $35,436 - $42,197
2,174 Added 3.43%
65,569 $1.27 Million
Q1 2023

May 15, 2023

BUY
$16.3 - $19.41 $1.07 Million - $1.27 Million
65,569 New
65,569 $1.27 Million
Q3 2020

Nov 13, 2020

SELL
$20.67 - $26.94 $12,939 - $16,864
-626 Closed
0 $0
Q2 2020

Aug 19, 2020

SELL
$16.46 - $27.42 $197 - $329
-12 Reduced 1.88%
626 $15,000
Q1 2020

May 15, 2020

BUY
$14.46 - $21.8 $1,373 - $2,071
95 Added 17.5%
638 $11,000
Q4 2019

Feb 14, 2020

BUY
$15.15 - $18.89 $8,226 - $10,257
543 New
543 $10,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.9B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Orion Portfolio Solutions, LLC Portfolio

Follow Orion Portfolio Solutions, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orion Portfolio Solutions, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orion Portfolio Solutions, LLC with notifications on news.